Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649557 | 1.00 | KDM1A (0.55) | KDM1AMAOBDRD2KMT2AL3MBTL1 | |
| SCHEMBL18615474 | 0.87 | NR1H4 (0.58) | KDM1AMAOBDRD2KMT2ADRD3 | |
| SCHEMBL18615464 | 0.84 | BTK (0.49) | KDM1AMAOBDRD2DRD3ACACB | |
| SCHEMBL18615433 | 0.84 | BTK (0.49) | KDM1AMAOBDRD2DRD3EPHX2 | |
| SCHEMBL8215672 | 0.82 | KDM1A (0.53) | KDM1AMAOBDRD2KMT2AL3MBTL1 | |
| SCHEMBL1412244 | 0.82 | ALDH1A1 (0.66) | KDM1AMAOBDRD2KMT2AL3MBTL1 | |
| SCHEMBL7467219 | 0.82 | KMT2A (0.58) | KDM1AMAOBDRD2KMT2AL3MBTL1 | |
| SCHEMBL22309838 | 0.81 | DRD2 (0.46) | KDM1AMAOBDRD2KMT2AL3MBTL1 | |
| SCHEMBL22309832 | 0.81 | DRD2 (0.46) | KDM1AMAOBDRD2KMT2AL3MBTL1 | |
| SCHEMBL2647959 | 0.80 | KDM1A (0.62) | KDM1AMAOBDRD2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | KDM1A 2654/4885MAOB 3598/4885DRD2 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.